Months af­ter ax­ing a Duchenne pro­gram and lay­ing off dozens, San­thera claims a win there with a dif­fer­ent pro­gram

5 years ago
R&D

No­var­tis plots 'next fron­tier' of MS treat­ment — and it could spell a buy­out for a small Swiss play­er

5 years ago
Deals

Mi­rati wins over a Chi­nese part­ner for KRAS hope­ful, look­ing to tail Am­gen's break­through win

5 years ago
Deals

Clin­i­cal stud­ies for AB Sci­ence's all-pur­pose an­ti-in­flam­ma­to­ry drug grind to a halt as com­pa­ny flags po­ten­tial risk ...

5 years ago
R&D

Five more biotechs file their SEC pa­per­work as the IPO Class of 2021 swells to 60

5 years ago
Financing

Alk­er­mes wins FDA nod for com­bo med with an­tipsy­chot­ic olan­za­p­ine — this time with­out the weight gain red flags

5 years ago
FDA+

Covid-19 roundup: Mod­er­na sub­mits vac­cine for full ap­proval; WHO un­veils new Greek-based sys­tem for nam­ing vari­ants

5 years ago
Coronavirus

Biden HHS seeks to dis­miss PhRMA’s law­suit to stop Cana­di­an drug im­ports

5 years ago
Pharma
FDA+

No­var­tis scraps a slate of Beovu tri­als af­ter 4-week dos­ing turned up safe­ty is­sues — dash­ing hopes of de­thron­ing ...

5 years ago
R&D
Pharma

Biden 2022 bud­get wish list calls for Medicare ne­go­ti­a­tions on drug prices, new $6.5B NIH agency

5 years ago
FDA+

Sanofi slash­es an­oth­er pro­gram for key mol­e­cule, while keep­ing hopes in hand­ful of rare dis­eases

5 years ago
R&D
Pharma

Ex­clu­sive: Helsinn chief Ric­car­do Braglia spells out a block­buster plan to take the fam­i­ly phar­ma pub­lic — with an ...

5 years ago
Financing
Bioregnum

Am­gen beefs up its late-stage pipeline with a $400M cash deal to go up against heavy­weight ri­vals in a PhI­II atopic ...

5 years ago
Deals

Lat­est news: Am­gen's land­mark OK for KRAS drug, in­side Ver­tex 3.0, the big hunt for CAR-T in sol­id tu­mors, and more

5 years ago
Weekly

Am­gen cracks the un­drug­gable code, earn­ing the FDA's nod for first-ever KRAS in­hibitor

5 years ago
Pharma
FDA+

FDA hands a CRL to drug­mak­er Eton af­ter a de­layed in­spec­tion — but are Covid-19 trav­el re­stric­tions re­al­ly the ...

5 years ago
R&D
FDA+

Re­cur­sion CSO heads west for mi­ni-brain up­start; No­var­tis vet steps up to the plate as CFO for An­drew Hirsch at C4 ...

5 years ago
Peer Review

Covid-19 roundup: UK au­tho­rizes J&J vac­cine; UNICEF buys 220 mil­lion dos­es of Russ­ian vac­cine

5 years ago
Coronavirus

Chi­na's patent law re­vi­sions set to take ef­fect June 1; Ver­ri­ca's sec­ond trip to the FDA is de­layed

5 years ago
News Briefing

With two de­buts and a SPAC, bio­phar­ma notch­es an­oth­er busy week as IPO raise soars past $7B

5 years ago
Financing

Bio­haven earns pre­ven­ta­tive nod for mi­graine med Nurtec, snar­ing a much-need­ed leg up over Ab­b­Vie

5 years ago
Pharma
FDA+

No price com­pe­ti­tion in PD-(L)1? That might not last long as EQRx, CStone read out late-stage win for chal­lenger

5 years ago
R&D

The man­u­fac­tur­ing hold at Emer­gen­t's Bal­ti­more Bayview plant could be com­ing to an end — re­port

5 years ago
Coronavirus
Manufacturing

Bris­tol My­ers gets its first GI drug ap­proval, and it comes from a long­time Cel­gene MS pro­gram

5 years ago
FDA+
First page Previous page 696697698699700701702 Next page Last page
A service from the Financial Times